Research Priorities To Fight Drug-Resistant Tuberculosis
Link: Research Priorities To Fight Drug-Resistant Tuberculosis.
Tuberculosis (TB) has long been one of the world's great killers. Now, forms of drug-resistant TB--multidrug (MDR) and extensively drug-resistant (XDR)--are occurring at an ominous and accelerating rate. To help in the fight against drug-resistant TB, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has formulated an MDR and XDR TB research agenda.
A summary of the agenda, authored by NIAID Director Anthony S. Fauci, M.D., and members of the NIAID Tuberculosis Working Group, is now available online in The Journal of Infectious Diseases.
"The TB diagnostic tools in use today are antiquated, slow and insensitive; TB drug regimens are complex and lengthy; and the only vaccine available does not provide effective protection against adult pulmonary TB," says Dr. Fauci. "The challenge of TB control is further compounded by the rise of drug-resistant TB, and we anticipate that the NIAID Research Agenda for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis will contribute substantively to the fight against this emerging threat."